Intriguingly, in a current study, ErbB2 amplification was recognized as an unacknowledged mechanism mediating the acquired TKIs resistance of NSCLC with the absence of the EGFR T790 M mutation [45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.